Genomic Vision Inks Chinese Distribution Deal with APG Bio Ltd
June 19 2017 - 2:00AM
Business Wire
The Company reinforces its international
exposure and commercial outreach through an alliance with a leading
distributor in Asia (China, Hong-Kong and Macau)
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV), a company
specialized in the development of diagnostic solutions for the
early detection of cancers and genetic diseases today announced it
has signed a business alliance with APG Bio Ltd to distribute its
solutions and services for the life sciences research (LSR) market
in Great China, Hong-Kong and Macau.
“We are pleased to announce we have reached an exclusive
agreement with Genomic Vision to distribute the molecular combing
technology in China, Hong-Kong and Macau. This innovative
technology will bring new approaches for genomic analysis to our
customers and will strongly broaden our Life Science portfolio.”,
commented Haixang Wang, CEO of APG Bio Ltd.
David Del Bourgo, Director of Marketing & Sales said:
“We are delighted to start this distribution agreement with APG Bio
Ltd. China is today a leading player in the world of genomics and
we know there is a tremendous potential for our technology to
contribute to the country developments in that field. By this
distribution alliance with APG Bio Ltd, a recognised player in
China and its neighboring markets, Genomic Vision will sustainably
improve the international expansion of its LSR activities.”
Thanks to the DNA combing technology, Genomic Vision is ideally
suited for applications in the exciting area of the genome editing.
The cutting-edge solutions and services developed by the Company
enable to detect complex genetic anomalies responsible for
hereditary diseases and cancers by offering a full and
comprehensive view of entire DNA molecules.
APG Bio Ltd is a leading distributor in China. Headquartered in
Shanghai, the Company numbers 180 dealer partners nationwide,
offering innovative instrument and reagent solutions to the life
science and industrial markets. APG Bio Ltd, with professional
technical support and application support, is also committed to
provide researchers perfect pre-sale consultation and after-sale
service. (http://en.apgbio.com)
ABOUT GENOMIC VISION
GENOMIC VISION is a company specialized in the development of
diagnostic solutions for the early detection of cancers and serious
genetic diseases and tools for life sciences research. Through the
DNA Molecular Combing, a strong proprietary technology allowing to
identify genetic abnormalities, GENOMIC VISION stimulates the
R&D productivity of the pharmaceutical companies, the leaders
of the diagnostic industry and the research labs. The Company
develops a robust portfolio of diagnostic tests (breast, ovarian
and colorectal cancers, myopathies) and analysis tools (DNA
replication, biomarkers discovery, gene editing quality control).
Based near Paris, in Bagneux, the Company has approximately 60
employees. GENOMIC VISION is a public listed company listed in
compartment C of Euronext’s regulated market in Paris (Euronext: GV
- ISIN: FR0011799907). For further information, please visit
www.genomicvision.com
Member of CAC® Mid & Small and
CAC® All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section in its Document
de Reference filed with the French Autorité des Marchés Financiers
(AMF) on March 28, 2017, under number R.17-009, available on the
web site of Genomic Vision (www.genomicvision.com) and to the
development of economic conditions, financial markets and the
markets in which Genomic Vision operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Genomic Vision or not currently considered
material by Genomic Vision. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance
or achievements of Genomic Vision to be materially different from
such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170618005111/en/
Genomic VisionAaron Bensimon, +33 1 49 08 07
50Co-founder, Chairman &
CEOinvestisseurs@genomicvision.comorMilestonesPress
RelationsBruno Arabian, +33 1 83 62 34
84barabian@milestones.frorNewCapInvestor RelationsDušan
Orešanský / Emmanuel Huynh, +33 1 44 71 94 92gv@newcap.eu
Goldfield (AMEX:GV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Goldfield (AMEX:GV)
Historical Stock Chart
From Apr 2023 to Apr 2024